|Articles|July 27, 2018
Global Disease Burden of Hepatitis B Tops SPT Week in Review
Author(s)SPT Staff
Top news of the week from Specialty Pharmacy Times.
Advertisement
5. Consolidation: Reshaping Pharmacy and Beyond
There is a concern that mergers and acquisitions in the pharmacy space will lead to decreased competition and loose agreements between companies that will not drive significant outcomes.
4. FDA Approves Second Biosimilar to Neupogen
The FDA approved Pfizer's filgrastim-aafi, a filgrastim biosimilar to Amgen's Neupogen.
3. Injection Drug Users Can Benefit from a Partially Effective Hepatitis C Vaccine
Researchers estimated whether a hepatitis C vaccine could reduce transmission of the virus among injection drug users, even without providing complete immunity.
2. FDA OKs New Drug for Endometriosis Pain Management
Officials with the FDA have approved elagolix (Orilissa, AbbVie), a product specifically developed for women with moderate to severe endometriosis pain.
1. Global Treatment Coverage of Hepatitis B Lagging
Taking advantage of cost-effective generic medications can improve access to hepatitis B treatment, especially in countries with a high disease burden.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Updated Indication for Upadacitinib in Patients With IBD
2
CDC Layoffs Raise Questions About the Future of Public Health Surveillance
3
From $200,000 in Student Loan Debt to Becoming a 7-Figure Pharmacist
4
Inhaled Insulin Demonstrates Comparable Safety, Lung Function, and Efficacy to Injectable Insulin in Type 1 Diabetes
5
